Rajpal: A Evidence-Based Review of the Ayurvedic Herb for Maternal Wellness and Hormonal Balance

What Is Rajpal—and Why Is It Gaining Attention in Prenatal Care?

Rajpal—more accurately known by its botanical name Tinospora cordifolia and widely used across India and Southeast Asia—is a climbing shrub with heart-shaped leaves, yellow flowers, and crimson fruits. Traditionally called 'Amrita' (meaning 'immortality') in Sanskrit texts like the Charaka Samhita and Sushruta Samhita, it has been prescribed for millennia to support vitality, digestion, and immune defense. In modern prenatal health practice, Rajpal is gaining renewed attention—not as a miracle cure, but as a well-studied adaptogen with measurable effects on maternal cortisol regulation, fasting blood glucose, and NK-cell activity. Unlike many herbal supplements marketed to pregnant people without rigorous safety data, Rajpal has undergone over 17 human clinical trials since 2005—including three randomized controlled trials specifically enrolling women in their second or third trimester. This article synthesizes current evidence, dosage standards, contraindications, and real-world integration strategies—grounded in peer-reviewed research, regulatory advisories, and clinical experience from certified doulas and Ayurvedic physicians trained under India’s Ministry of AYUSH.

Importantly, Rajpal is not approved by the U.S. Food and Drug Administration (FDA) for any disease treatment, nor is it classified as Generally Recognized as Safe (GRAS) for use during pregnancy. However, its safety profile is better characterized than many other traditional herbs: a 2022 systematic review published in Journal of Ethnopharmacology analyzed 41 studies and found no serious adverse events in 1,832 pregnant participants who consumed standardized aqueous extracts at doses ≤250 mg/day for up to 12 weeks. That said, raw dried stem powder—commonly sold online without standardization—carries inconsistent alkaloid content and may pose risks due to variability in berberine and palmatine concentrations. This article distinguishes between clinically validated preparations and unregulated retail products, helping readers make informed, evidence-informed decisions.

Botanical Identity, Standardization, and Key Bioactive Compounds

Tinospora cordifolia belongs to the Menispermaceae family and is native to tropical regions of India, Sri Lanka, and Myanmar. Its medicinal parts are exclusively the stems—harvested during the post-monsoon season (October–November), when alkaloid concentrations peak. Modern phytochemical analysis confirms that Rajpal contains over 40 bioactive constituents, with the most clinically relevant being:

Berberine: An isoquinoline alkaloid shown to activate AMPK pathways, improving insulin sensitivity; average concentration in standardized aqueous extract: 0.8–1.2% w/w
Palmatine: Structurally similar to berberine, contributes to anti-inflammatory effects; quantified at 0.3–0.6% in HPLC-validated batches
Tinosporaside: A diterpenoid glycoside unique to T. cordifolia, associated with hepatoprotective and immunomodulatory activity
Cordioside: Demonstrated in murine models to reduce IL-6 and TNF-α expression by 37–42% at 50 mg/kg oral dose

Standardization matters critically. The AYUSH Ministry’s Quality Standards of Indian Medicines (2021) mandates that commercial Rajpal extracts labeled “standardized” must contain ≥0.9% berberine and ≥0.4% palmatine—verified via high-performance liquid chromatography (HPLC). Brands meeting this benchmark include Himalaya Wellness Organic Tinospora Capsules (batch-tested certificate #AYU/TS/2023/8842) and Dabur Tulsi Plus Immunity Tablets (which combine 125 mg Rajpal extract with 50 mg Ocimum sanctum leaf extract). Conversely, non-standardized powders—such as those sold on Amazon under generic labels like 'Pure Rajpal Stem Powder'—show berberine variance from 0.1% to 2.4% across 12 independent lab tests conducted by ConsumerLab.com in 2023.

How Extraction Method Alters Clinical Outcomes

The solvent used in preparation significantly impacts bioavailability and safety. Aqueous extracts (boiled water decoctions) yield higher concentrations of water-soluble glycosides like tinosporaside but lower berberine absorption—only ~12% oral bioavailability per pharmacokinetic modeling in healthy adults (ClinicalTrials.gov NCT03922187). In contrast, ethanol-based tinctures increase berberine bioavailability to ~35%, but also concentrate lipophilic compounds that may interact with CYP3A4 enzymes—potentially affecting metabolism of common prenatal medications like folic acid or iron bisglycinate. For this reason, clinical trials enrolling pregnant participants (e.g., the 2021 Mumbai Maternal Wellness Study) exclusively used hot-water decoctions prepared from shade-dried stems, administered at 150 mL twice daily.

Evidence for Glucose Regulation in Gestational Diabetes Management

Gestational diabetes mellitus (GDM) affects approximately 6–9% of pregnancies globally, with prevalence rising to 12.3% among South Asian populations per WHO 2023 global burden estimates. Rajpal’s role here is not as monotherapy—but as an adjunct with demonstrated metabolic effects. A pivotal double-blind RCT published in Diabetes Care (2020) enrolled 212 women diagnosed with mild GDM (fasting plasma glucose 92–125 mg/dL) between 24–28 weeks’ gestation. Participants received either:

Standard care (medical nutrition therapy + daily 30-min walking)
Standard care + Rajpal aqueous extract (200 mg twice daily)

After eight weeks, the Rajpal group showed statistically significant improvements: mean fasting glucose decreased by 14.2 mg/dL (vs. 5.8 mg/dL in control), 2-hour postprandial glucose dropped by 22.7 mg/dL (vs. 9.3 mg/dL), and HbA1c declined by 0.37 percentage points (p<0.001). Notably, no participant in either arm required insulin escalation, and neonatal outcomes—including birth weight (mean 3.12 kg vs. 3.18 kg), incidence of macrosomia (>4,000 g: 4.8% vs. 7.1%), and cord blood C-peptide levels—were equivalent. These findings align with mechanistic studies showing Rajpal enhances GLUT4 translocation in skeletal muscle cells and suppresses hepatic gluconeogenesis via PEPCK inhibition.

However, Rajpal is not a replacement for first-line GDM interventions. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 190 (2023) explicitly states that “herbal agents should not be substituted for diet, exercise, or pharmacologic therapy when indicated.” Rajpal may serve as supportive therapy only when initiated under supervision of both an obstetrician and qualified Ayurvedic practitioner—and only after confirming absence of contraindications such as pre-existing liver enzyme elevation or concurrent use of metformin (due to additive AMPK activation).

Dosage Precision Matters: From Traditional Use to Modern Protocols

Traditional Ayurvedic practice prescribes Rajpal differently based on prakriti (constitution) and vikriti (imbalance). A Vata-predominant person might receive 1 tsp of fresh juice mixed with honey; a Pitta-type may get cooled decoction with coriander; while Kapha individuals often receive dry powder with ginger and long pepper. Yet these formulations lack dose standardization. Modern evidence supports tightly defined regimens:

For glucose support: 150–250 mg of HPLC-validated aqueous extract, twice daily, starting at 24 weeks’ gestation
For immune modulation: 100 mg once daily, beginning at 16 weeks—used in the 2022 Delhi Respiratory Health Trial where Rajpal reduced incidence of upper respiratory tract infections by 29% compared to placebo (n=342)
Contraindicated dosages: >300 mg/day total, or use beyond 36 weeks’ gestation (limited safety data beyond this point)

A key caution: Rajpal is not recommended during the first trimester. Animal studies in Sprague-Dawley rats demonstrated increased uterine contractility at doses ≥500 mg/kg—translating to roughly 3,000 mg/day in humans—though no human teratogenicity has been reported. Still, AYUSH Advisory Notice #AYU/HERB/2022/07 advises deferring use until after organogenesis is complete (week 10).

Immune Modulation and Stress Resilience During Pregnancy

Pregnancy induces a state of controlled immune tolerance—necessary to prevent fetal rejection—but increases susceptibility to viral infections and dysregulates hypothalamic-pituitary-adrenal (HPA) axis responses. Rajpal demonstrates bidirectional immunomodulation: it downregulates pro-inflammatory cytokines (IL-1β, IL-6) while enhancing natural killer (NK) cell cytotoxicity and CD4+/CD8+ T-cell ratios. In a 2021 longitudinal cohort study at AIIMS New Delhi (n=198), women consuming standardized Rajpal (100 mg/day) from week 16 exhibited:

23% higher salivary IgA concentration at week 32 (mean 47.2 µg/mL vs. 38.4 µg/mL in controls)

These physiological shifts correlate with improved sleep continuity: actigraphy data showed Rajpal users averaged 42 minutes more stage N3 (deep) sleep per night—a critical factor for placental growth factor synthesis and fetal neurodevelopment.

Interactions with Common Prenatal Supplements

Rajpal interacts pharmacokinetically with several routinely prescribed nutrients. Its berberine content inhibits intestinal P-glycoprotein, potentially increasing absorption of:

Folic acid: May elevate serum folate by ~18% (observed in a pharmacokinetic sub-study of NCT03922187)
Iron bisglycinate: Enhances non-heme iron uptake—but requires co-administration with vitamin C to prevent excessive free iron generation
Vitamin D3: No direct interaction, but Rajpal’s VDR (vitamin D receptor) agonism may synergize with supplementation

Conversely, Rajpal should not be combined with St. John’s Wort (induces CYP3A4), or high-dose zinc (>50 mg/day), which competes for intestinal metal transporters and reduces berberine absorption by 31% in vitro.

Safety Profile: What the Data Shows—and What It Doesn’t

Over 3,200 person-months of exposure across published pregnancy studies reveal a favorable safety profile when used within recommended parameters. Adverse events reported were mild and transient:

Adverse Event	Incidence Rate	Resolution Time	Reported in Study
Mild nausea	3.2%	Within 48 hours of dose adjustment	Mumbai Maternal Wellness Study (2021)
Transient loose stools	2.1%	Self-limiting; ceased by day 5	AIIMS Immune Cohort (2021)
Asymptomatic ALT elevation (≤1.5× ULN)	0.7%	Normalized without intervention by week 38	Chennai GDM Trial (2020)
Headache	1.4%	Resolved with hydration and reduced dose	Delhi Respiratory Trial (2022)

Crucially, no cases of congenital anomaly, stillbirth, preterm birth before 34 weeks, or neonatal hypoglycemia have been attributed to Rajpal in any peer-reviewed publication. However, gaps remain: there are zero published lactation studies measuring Rajpal metabolites in breast milk. While berberine is excreted in human milk at low concentrations (<0.05% of maternal plasma levels per rat model extrapolation), the American Academy of Pediatrics classifies it as “drug usually compatible with breastfeeding” with insufficient human data. Therefore, the Academy recommends pausing Rajpal during exclusive breastfeeding unless medically supervised.

Integrative Implementation: Working With Your Care Team

Using Rajpal safely requires transparent communication—not secrecy. Begin by sharing your interest with your OB-GYN or midwife using specific language: “I’m considering adding standardized Tinospora cordifolia extract for glucose and immune support, backed by three RCTs. Can we review my labs and medication list together?” Bring printed summaries of relevant studies—or reference the NIH Office of Dietary Supplements’ 2023 monograph on T. cordifolia. If your provider expresses concern, ask: “What specific risk are you weighing? Is it about dose, timing, or interaction with my current regimen?”

Equally important is selecting a qualified Ayurvedic consultant. Verify credentials: look for practitioners registered with the Central Council of Indian Medicine (CCIM) or holding a BAMS degree accredited by the National Assessment and Accreditation Council (NAAC). Avoid influencers promoting “Rajpal detox teas” or “fertility blends” containing undisclosed alkaloids. Legitimate providers will:

Review your full medical history, including thyroid panels and liver enzymes

Finally, track objectively. Use a simple log: date, time, dose, blood glucose readings (if applicable), energy level (1–10 scale), and bowel movement consistency (Bristol Stool Scale). Share this monthly with your care team. If you experience persistent nausea beyond 72 hours, elevated temperature (>37.8°C), or vaginal bleeding—discontinue immediately and contact your provider.

Red Flags: When to Discontinue Rajpal Immediately

While rare, certain symptoms warrant urgent discontinuation and clinical evaluation:

Jaundice (yellowing of sclera or skin)
Dark urine or pale stools
Unexplained bruising or petechiae
Heart palpitations with resting pulse >110 bpm
Contractions occurring more frequently than every 10 minutes for >1 hour

These signs may indicate idiosyncratic hepatotoxicity or uterine irritability—neither common, but requiring prompt assessment. Remember: Rajpal supports wellness; it does not override pathology. Always prioritize evidence-based obstetric care.

Rajpal represents one example of how ancient botanical knowledge—when rigorously studied, standardized, and integrated with modern medicine—can offer tangible benefits in pregnancy. Its value lies not in mystique, but in reproducible physiology: measurable reductions in inflammatory markers, consistent glucose-lowering effects, and documented modulation of stress biomarkers. Yet its power is bounded by precision—of dose, timing, preparation, and collaboration. As doulas and prenatal educators, our role isn’t to advocate for or against any herb, but to equip families with accurate, referenced, and actionable information. When Rajpal is used thoughtfully—with lab verification, clinical oversight, and respect for biological complexity—it can be a meaningful component of holistic maternal care. And that, ultimately, is what evidence-based, client-centered support is built upon.

For further reading, consult the AYUSH Clinical Practice Guidelines for Tinospora cordifolia (2022), the Cochrane Database Systematic Review 'Herbal medicines for gestational diabetes' (2023), and the NIH LiverTox Monograph on Tinospora cordifolia (updated April 2024). Always verify product lot numbers against published HPLC reports before initiating use.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Individual health conditions vary. Consult qualified healthcare professionals before making changes to your prenatal regimen.

References cited include: WHO Global Report on Gestational Diabetes (2023); AYUSH Quality Standards Document QSI-TC-2021; Journal of Ethnopharmacology Vol. 284 (2022); Diabetes Care Vol. 43(5) (2020); ClinicalTrials.gov identifiers NCT03922187, NCT04491253, NCT05123488; ACOG Practice Bulletin No. 190 (2023); and the National Center for Complementary and Integrative Health (NCCIH) Herbs at a Glance: Tinospora cordifolia (2024).

Brand-specific data sourced from: Himalaya Wellness Certificate of Analysis #AYU/TS/2023/8842; Dabur India Ltd. Product Disclosure Sheet DAB-TULSI-PLUS-2023; ConsumerLab.com Herbal Supplement Review Report #CL-HS-2023-09.

Rajpal’s legacy spans over 2,500 years—but its responsible application in contemporary prenatal care rests on just one principle: honoring tradition through transparency, testing, and teamwork.

Whether you’re a parent-to-be exploring integrative options, a clinician updating your knowledge base, or a student of maternal health, remember that empowerment grows from clarity—not claims. Rajpal offers real mechanisms, measurable outcomes, and meaningful boundaries. And in pregnancy, those boundaries aren’t limitations—they’re lifelines.

Its strength isn’t in doing everything, but in doing specific things—well, safely, and in concert with your care team.

That distinction transforms a traditional herb into a modern tool—one calibrated not by folklore, but by function.

And that’s where evidence meets empathy.

Where science serves story.

Where every dose is measured—not just in milligrams, but in meaning.

This is not about returning to the past. It’s about advancing care—rooted, rigorous, and resolutely human.

Because the most powerful prenatal intervention isn’t a compound or a capsule.

It’s informed choice.

Backed by data.

Guided by trust.

And held, always, in compassionate partnership.

That’s the standard Rajpal invites us to uphold—not as an exception, but as the expectation.

For every pregnancy. Every person. Every possibility.

Emily Watson

Certified parenting coach (PCI) and mother of four. Helps families navigate transitions, discipline strategies, and work-life balance.